Neurocrine Biosciences awarded director Kevin Charles 14,343 shares at $0, changing his reported ownership record. Investors can distinguish the grant from a separate forfeiture of 7,839 shares at $156.22 per share, with the transactions representing about 2.7% and 1.5% of their respective holdings.

Key Highlights

  • Transaction code A classified the award as a grant to director Kevin Charles.
  • A separate code F transaction covered 7,839 forfeited shares at $156.22 per share.
  • The award represented about 2.7% of the resulting holding, while the forfeiture represented about 1.5% of the prior holding.

NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) awarded director GORMAN KEVIN CHARLES 14,343 shares at $0 on September 11, 2026.

Award and Forfeiture Entries Recorded

A separate code F entry records the forfeiture of 7,839 shares at $156.22 per share on September 11, 2026. The price applies to the forfeited shares, not the award. Charles held 517,797 shares after that forfeiture.

Reported Holdings Use Different Ownership Bases

The award represented about 2.7% of Charles’ resulting share holding. His ownership after the award was 525,636 shares. The forfeiture represented about 1.5% of his prior share holding, before the reported post-forfeiture balance of 517,797 shares. The award percentage uses the resulting holding, while the forfeiture percentage uses the prior holding.